Infiuss Health Inc
What is the name of your solution?
Provide a one-line summary of your solution.
Platform for remote clinical trials for Africa
Film your elevator pitch.
What specific problem are you solving?
1.4 Billion Africans (the most diverse population on the planet) are excluded from clinical research studies today because it takes an average of 12-18 months to recruit participants and engage with them to take part in these studies. This leads to researchers missing out on huge amounts of data that could be generated from studying this population and exposing us to drugs and vaccines tested on predominantly white and European participants.
What is your solution?
We are building a decentralized clinical trials platform(the first of its kind in Africa) to power remote research/clinical trials in Africa, by connecting researchers and pharma companies directly to participants for their clinical research studies in under 60mins with a 98% accuracy.
Our all-in-one software helps researchers remotely recruit participants in under 60mins, collect e-consent, collect and analyze data and provide virtual support. We also provide them with the ability to find the right sites and principal investigators for running these studies.
Who does your solution serve, and in what ways will the solution impact their lives?
Pharma companies and researchers, working on clinical trials and medical research, need more diverse participant pools. These participants help them determine the safety and efficacy of new therapies before they are made available to the general public making sure that we get drugs, vaccines, and medical devices that are applicable and generalizable to a wide range of people. They also want to do this in a manner that is both time and cost-efficient. Pre-covid, clinical trial recruitment was a long process that was very manual, required and required a lot of reseaources and expensive 3rd party CRO's to recruit and engage participants across various trial or research sites.
How are you and your team well-positioned to deliver this solution?
We are an 8 man team led by Melissa Bime a registered nurse. My Co-founder Charles previously worked at Microsoft Nigeria before leaving to become CTO at infiuss health.
Dr Tanyi Pride is a neurologist and our Chief Scientific Officer, is in charge of research operations across Nigeria and Cameroon. Udeme Asuama our Chief operations officer has had over 15 years of experience working across various contract research Organisations in the US.
Dr Lincoln Mokia is is our Chief od site and PI selection.Dr lincoln worked for IQVIA Nigeria and head of site selection for 8years before joining us full time.
Peregrine Nkwain, we is head of product and growth.
And finally we have Vera Mbengwi and Micheal Isah who handle sales and marketing in Buffalo Newyork.
Which dimension of the Challenge does your solution most closely address?
Improve confidence in, engagement with, and use of healthcare services globally.
Where our solution team is headquartered or located:Buffalo, NY, USA
Our solution's stage of development:Growth
How many people does your solution currently serve?
Why are you applying to Solve?
1. Access to Capital; It is hard for us to get access the operating capital we need. Being a female founder access to capital has been a challenge.
2. Access to Mentorship and potential opportunities for collaboration with other challenge winners.
In which of the following areas do you most need partners or support?
Financial (e.g. improving accounting practices, pitching to investors)
Who is the Team Lead for your solution?
What makes your solution innovative?
Our platform, PROBE, a decentralized clinical trial platform that's the first of its type in Africa allows for sponsors to recruit the most eligible participants in under 60mins with a 98% accuracy as well as locate the best sites and Primary Investigators for facilitating fully remote and hybrid clinical trials.
We are building the blueprint to help navigate running clinical trials in Africa, We have also built API’s that facilitate interoperability with other DCT’s.
Our technology is a distant second to our on-the-ground approach. To help negotiate the regulatory landscape that comes with such dynamic geography, we've worked with local regulatory coordinators and ministries of health.
Our field research coordinators collaborate with local partners to recruit volunteers from all demographics, regardless of whether or not they have access to a smartphone or the internet, reducing recruitment bias. We are developing the blueprint for attracting and retaining clinical research participants across Africa while expediting clinical trial timelines and ensuring diversity.
What are your impact goals for the next year and the next five years, and how will you achieve them?
Today over 1.4 Billion Africans (the most diverse population) have no easy way to part in clinical trials. This means researchers miss out on a huge amount of data that can be used to advance research in areas such as drug/vaccine discovery. Our goal over the next 5years is to build the largest and most diverse database of patients and participants across Africa and increase the reprsentation of Africans in medical research, which will benefit Africans and provide researchers with more data to make decisions
How are you measuring your progress toward your impact goals?
So far we currently have 15,000+ monthly active participants who’ve participated in 62 trials completed on Infiuss. Started with Covid19 (240+ researchers in Nigeria and Francophone Africa have used Infiuss for nationwide trials) and recently signed with Sanaria Inc, US biotech company to power their malaria vaccine clinical trials on 280,000 Participants in West Africa
We have lots of experiments to keep growing exponentially: 12 CROs have reached out to use our software to execute contracts they have (it’s their only way to survive in covid times ;), we’re talking to Curebase (YC-backed) to built on their APIs to give their clients access to African participants. Last year, the Decentralized Trials and Research Alliance was created made up of 50+ life sciences cos funding 75% of clinical trial research (Pfizer, AstraZeneca, etc.) and health orgs like FDA. We’re currently talking to some of the members to have on-the-table access to research projects and be the de facto platform for getting participants in Africa.
What is your theory of change?
Covid-19 is the digital acceleration of the decade. Since May 2020, decentralized trials have been the new normal, as participants are reluctant to visit clinics and digital collaboration encouraged. Pharmaceuticals and Medical technology developers need to be physically present or use Consultant Research Organisations (CROs) to launch clinical trials and patient recruitment in Africa. They take 6-12 months to reach 40% enrollment targets, using traditional methods: manually sourcing and engaging participants in hospitals.
We are doing this by putting the following processes in place.;
Supply side: we’re starting with sourcing participants in Nigeria and Francophone Africa, representing over half a billion Africans. We pull eligible participants into our software from our current network of 50 hospitals in Nigeria and Francophone Africa. Also interconnected our platform to 4 EHRs (exclusive agreements) automating our patient acquisition efforts. Growing number of hospitals and EHR partners as we get researchers in other countries. Database to grow from 15,000+ participants today to over 100,000 this year.
Demand side: There’s been a lot of word of mouth from pharma and researchers using our platform. We spend $0 on marketing. Medical schools and teaching hospitals carry out 55% of clinical trials and have been our ambassadors, leading us to big pharma like Sanaria Inc and GAVI. We also use the clinicaltrials.gov website to get information on clinical studies being carried out on a country by country basis and information on those actively recruiting participants.
Describe the core technology that powers your solution.
At Infiuss Health, we implement the most recent, advanced and cutting-edge
technologies in building and managing our web platforms and to deliver a seamless and intuitive user experience for all our users(on web and mobile).
For our web and AI-powered back-end, we make use of PHP (Laravel), NodeJS (Adonis.js & Sails.js), Redis, Pusher, Algolia, and many others.
On the Relational Database Management System (RDBMS) side, we primarily use PostgreSQL & MySQL as our central data store.
Our platform is hosted on AWS (through Heroku PaaS) and on our own company dedicated VPS. We equally have integrations for third-party services on the Infiuss Health Research Platform.
Which of the following categories best describes your solution?
A new business model or process that relies on technology to be successful
Please select the technologies currently used in your solution:
Which of the UN Sustainable Development Goals does your solution address?
What type of organization is your solution team?
For-profit, including B-Corp or similar models
How many people work on your solution team?
How long have you been working on your solution?
What is your approach to incorporating diversity, equity, and inclusivity into your work?
We are a 12 man team across 4 countries and 2 continents. The entire leadership team is composed of 60% women of color and 40% Men.
Recruiting a diverse team has never been a problem for us given our business itself if that of solving for diverstity in clinical trials.
My grandmother once told me, 'it is our differences that make us who we are and it is by respecting this differences that we grow'.
This saying hasgreatly impacted our approach to hiring candidates byensuring that they are a cultural fit first. It only takes one bad candidate to derail an entire company. During candidate interviews, we make deep dives to ensure that the candidates understand the multi cultural environment that we are. I have found that it helps to ensure that people make conscious decisions on how to treat each other within the team with respect and consideration.
What is your business model?
We license our software from $10K/year for industry (pharma, medical technology developers) and $50/month to academia (independent physicians and researchers). We’re on track to do $60K MRR this month and have secured deals to 3-5x monthly revenue in Q2. In the next 18 months, we plan to be in 6 countries across Africa, with patient data from 200+ hospitals, generating $300K MRR.
Of the $60B spent globally for clinical research studies annually, Africa only capture about 10% of this, greatly as a result participant enrollment and engagement difficulties. This represents a $42B untapped niche market opportunity. In 5 years, we want to have the largest database of participants eligible for clinical research and doing ~$200M ARR
Do you primarily provide products or services directly to individuals, to other organizations, or to the government?Organizations (B2B)
What is your plan for becoming financially sustainable?
With over 21,000+ participants in our database, growing 25% MoM. We have 3 big contracts pushing us to exponentially grow our patient database: Genentech (a genomic testing company in the US) has partnered with us to recruit 50,000 participants over the next 18months to help with their biobanking efforts.
We've also signed with Sanaria Inc for malaria vaccine trials in Nigeria and we’re conducting pilot studies with the Bill Gates affiliated health org (GAVI) and the Global Fund, who are key stakeholders in a $30B African vaccine fund, to position our tech as de facto for participant recruitment for vaccine trials. These will grow our monthly revenue 3-5x in Q4 of 2022.